Key Insights

Highlights

Treatment Research

2 treatments under study, led by Imgn632

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03386513Phase 1/2Active Not Recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Showing all 1 trials

Research Network

Common Treatments

  • Imgn6321
  • Pivekimab Sunirine1

Active Sponsors

  • AbbVie1
  • Abbvie Deutschland GmbH & Co. KG1

Related Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm1
  • Myeloproliferative Neoplasm1

Activity Timeline